2022
DOI: 10.1016/j.jddst.2022.103852
|View full text |Cite
|
Sign up to set email alerts
|

Modified chitosan nanogel-polymersomes for oral co-delivery of oxaliplatin and rapamycin for synergistic chemotherapy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
4
0

Year Published

2023
2023
2025
2025

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(4 citation statements)
references
References 28 publications
0
4
0
Order By: Relevance
“…A number of experiments highlight the versatility of chitosan and its use in various anticancer applications, either as codelivery of oxaliplatin and rapamycin for synergistic chemotherapy [ 80 ] or by triggering other mechanisms, such as inhibition of the permeation-glycoprotein (P-gp), a protein with an important role in the management of cancer [ 81 ].…”
Section: Discussionmentioning
confidence: 99%
“…A number of experiments highlight the versatility of chitosan and its use in various anticancer applications, either as codelivery of oxaliplatin and rapamycin for synergistic chemotherapy [ 80 ] or by triggering other mechanisms, such as inhibition of the permeation-glycoprotein (P-gp), a protein with an important role in the management of cancer [ 81 ].…”
Section: Discussionmentioning
confidence: 99%
“…It has been reported that febrile temperatures can influence the differentiation and pathogenicity of T helper 17 cells, suggesting that polymersomes responsive to exogenous stimuli accompanied by thermal effects generation could potentially enhance T cell activation. In addition to the subcutaneous administration, recently reported orally administrable polymersomes enable mucosal immunization through polymersomes. The ideal candidate would be extremely stable in the acidic environment and respond to the basic environment of the intestinal tract to release both the antigen and adjuvants, thereby stimulating antigen-specific antitumor immunity. Other factors may affect the stimuli-responsive polymersomes application including the feasibility of the large production, the repeatability, the absolute biosafety in vivo in consideration of the inevitable organic solvent uses, etc .…”
Section: Conclusion and Future Perspectivesmentioning
confidence: 99%
“…Wande et al, in 2022, reported a nanogel-polymersomes drug delivery system based on modified chitosan, chitosan diacetate (CDA), methoxy-poly-(ethylene glycol)-b-poly (lactide) (MPP), and D-alpha-tocopheryl polyethylene glycol succinate (TPGS) with permeation-glycoprotein (P-gp) inhibition capability for enhancing the oral chemotherapy efficacy of erroneously soluble rapamycin and its synergistic chemotherapy with Oxaliplatin. The nanogel-polymersomes drug delivery system has tremendous potential for future cancer chemotherapy due to its surpassed Oxaliplatin, rapamycin, and Oxaliplatin and rapamycin mixtures (OR) in vitro cytotoxicity and in vivo antitumor chemotherapeutic efficacy [ 78 ]. In 2019, Mu and his team synthesized quercetin–chitosan conjugate (QT-CS) for oral delivery of doxorubicin (DOX) to improve its oral bioavailability by increasing its water solubility, opening tight junction and bypassing the P-glycoprotein (P-gp) [ 79 ].…”
Section: Applicability Of Chitosan-oriented Multifarious Deliverymentioning
confidence: 99%